Interferon-alpha-induced hepatitis C virus clearance restores p53 tumor suppressor more than direct-acting antivirals

Hepatology Communications

Volumn 1, Issue 3, 2017, Pages 256-269

  Aydin, Yucel ^a   Chatterjee, Animesh ^a   Chandra, Partha K ^a   Chava, Srinivas ^a   Chen, Weina ^a   Tandon, Anamika ^a   Dash, Asha ^a   Chedid, Milad ^a   Moehlen, Martin W ^a   Regenstein, Frederic ^a   Balart, Luis A ^a   Cohen, Ari ^b   Lu, Hua ^a   Wu, Tong ^a   Dash, Srikanta ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CHAPERONE; DIRECT ACTING ANTIVIRAL AGENT; LEDIPASVIR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; RIBAVIRIN; SOFOSBUVIR; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CHAPERONE-MEDIATED AUTOPHAGY; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; HEPATITIS C VIRUS; HUH-7.5 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYSOSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE; VIRAL CLEARANCE;

EID: 85028024233     PISSN: None     EISSN: 2471254X     Source Type: Journal    
DOI: 10.1002/hep4.1025     Document Type: Article

References (24)

1. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-726.
2. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J Hepatol 2016;65:727-733.
3. Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-747.
4. El-Serag HB, Kanwal F, Richardson P and Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with Hepatitis C virus infection. Hepatology 2016;64:130-137.
5. Wang M and Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer 2014;14:581-597.
6. Sato Y and Tsurumi T. Genome guardian p53 and viral infections. Rev Med Virol 2013;23:213-220.
7. Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 2013;19:879-888.
8. Zaika A, Wei J, Noto JM, Peek RM. Microbial Regulation of p53 tumor suppressor. PLOS Pathog 2015;11:e1005099.
9. Dash S, Chava S, Aydin Y, Chandra P, Ferraris P, Chen W, et al. Review: Hepatitis C virus infection induces autophagy as a prosurvival mechanism to alleviate hepatic ER-stress response. Viruses 2016;8:pii:E150.
10. Chandra PK, Bao L, Song K, Aboulnasr FM, Baker DP, Shores N, et al. HCV infection selectively impairs type I but not type III IFN signaling. Am J Pathol 2014;184:214-229.
11. Panigrahi R, Chandra PK, Ferraris P, Kurt R, Song K, Garry RF, et al. Persistent hepatitis C virus infection impairs ribavirin antiviral activity through clathrin-mediated trafficking of equilibrative nucleoside transporter 1. J Virol 2015;89:626-642.
12. McCloy RA, Rogers S, Caldon CE, Lorca T, Castro A, Burgess A. Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle 2014;13:1400-1412.
13. Jensen EJ. Quantitative analysis of histological staining and fluorescence using ImageJ. Anat Rec 2013;296:378-381.
14. Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. Nat Cell Biol 2013;15:713-720.
15. Arias E, Cuervo AM. Chaperone-mediated autophagy in protein quality control. Curr Opin Cell Biol 2011;23:184-189.
16. Meng X, Franklin DA, Dong J, Zhang Y. MDM2-p53 pathway in hepatocellular carcinoma. Can Res 2014;74:7161-7167.
17. Vakifahmetoglu-Norberg H, Kim M, Xia HG, Iwanicki MP, Ofengeim D, Coloff JL, et al. Chaperon-mediated autophagy degrades mutant p53. Genes Dev 2013;27:1718-1730.
18. Liu S, Xiao L, Nelson C, Hagedorn CH. A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses. PLoS One 2012;7:e44965.
19. Chandra PK, Gunduz F, Hazari S, Kurt R, Panigrahi R, Poat B, et al. Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. PLoS One 2014;9:e108616.
20. Asselah T, Bieche I, Mansouri A, Laurendeau I, Cazals-Hatem D, Feldmann G, et al. In vivo hepatic endoplasmic stress in patients with chronic hepatitis C. J Pathol 2010;221:264-274.
21. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-687.
22. Rusyn I, Lemon SM. Mechanisms of HCV induced liver cancer: what did we learn from in vitro and animal studies. Cancer Lett 2014;345:210-215.
23. Nishimura T, Kohara M, Izumi K, Kasama Y, Hirata Y, Huang Y, et al. Hepatitis C virus impairs p53 via persistent overexpression of 3beta-hydroxysterol Delta24-reductase. J Biol Chem 2009;284:36442-36452.
24. Duong FH, Dill MT, Matter MS, Makowska Z, Calabrese D, Dietsche T, et al. Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethynitrosamine mouse model through inhibition of p53. Carcinogenesis 2014;35:114-122.